Capstone Investment Advisors
KRYS icon

Capstone Investment Advisors’s Krystal Biotech KRYS Stock Holding History

Capstone Investment Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,196
Closed -$302K – 1984
2025
Q2 		$302K Buy
+2,196
New +$323K ﹤0.01% 1376
2024
Q1 		– Sell
-2,445
Closed -$303K – 2449
2023
Q4 		$303K Buy
+2,445
New +$271K ﹤0.01% 1587

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capstone Investment Advisors's KRYS Position: Q3 2025 in Review

Capstone Investment Advisors sold out of Krystal Biotech (KRYS) in Q3 2025, closing a stake of 2,196 shares — an estimated $302K sold.

Capstone Investment Advisors first reported a position in KRYS in Q4 2023 and held it in 2 quarters. The position peaked at $303K in Q4 2023. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

  • Capstone Investment Advisors reported no remaining Krystal Biotech position as of Q3 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 2,196 Krystal Biotech shares in Q3 2025, an estimated $302K.
  • Capstone Investment Advisors first reported a position in Krystal Biotech in Q4 2023 and held it in 2 quarters.
  • Capstone Investment Advisors's Krystal Biotech position peaked at $303K in Q4 2023.
  • 284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on Capstone Investment Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.